Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
DORTMUND, Germany, Dec. 20, 2016 -- PROTAGEN AG, a leading provider of pharma development services, novel diagnostic tests and companion diagnostics in the fields of immuno-oncology and autoimmune disease, today announced the successful completion a collaboration agreement with Novartis Pharma AG. During the collaboration, Protagen utilized its proprietary SeroTag technology to discover prediction as well as patient stratification markers for a novel drug being developed by Novartis.
Protagen CBO Georg Lautscham commented: “Our innovative SeroTag technology has proven on numerous occasions that it can monitor the immune-health status of patients, thereby allowing for the first time the systematic determination of response prediction and disease as well as patient stratification markers to select the most appropriate drug and therapy in autoimmune indications. This was evaluated in our collaboration with Novartis and we would like to thank Novartis’ R&D team for the excellent, productive and collaborative relationship.”
About Protagen – Diagnostics Differentiated
Headquartered in Dortmund Germany, Protagen specializes in Pharma development services and novel companion diagnostics, in the field of immuno-oncology and autoimmune disease.
Protagen uses its proprietary SeroTag biomarker discovery platform to identify valuable biomarkers that support Pharma development and its NavigAID products to personalize treatment with targeted therapies. With state-of-the-art bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies for cancer and autoimmune disease patients.
For more information, please visit www.protagen.com.
Company Contact: Dr. Georg Lautscham Chief Business Officer Protagen AG Otto-Hahn-Str. 15 44227 Dortmund T +49 231 9742 6300 [email protected] Media Inquiries: Matt Clawson SVP, Managing Director Pure Communications San Clemente, CA USA T +1 (949) 370-8500 [email protected]
